NICE rejects Bosulif
November 28, 2013Sales and Marketing CML, NHS, NICE, Pfizer, bosulif
In a blow for Pfizer NICE has categorically rejected the manufacturer’s Bosulif as a treatment for previously-treated chronic myeloid leukaemia …
Francis report author becomes Patients Association president
November 28, 2013Sales and Marketing Mid Staffs, NHS, robert francis, scandal
The author of a damning report into failings at the Staffordshire hospital has become the new president of the Patients …
PiR Resourcing hires client services director
November 28, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing perry evans, pir resourcing
Life science talent management firm PiR Resourcing has appointed industry veteran Perry Evans to be its Client Services director. PiR …
Government apps tackle alcohol abuse
November 28, 2013Medical Communications alcohol, apps, howe, obesity
The winners of a £2 million government competition to produce apps which will help combat alcohol abuse and weight gain …
Third failure for Sanofi/Merrimack cancer drug
November 27, 2013Research and Development, Sales and Marketing Cancer, Sanofi, merrimack, mm-121
Sanofi and partner Merrimack have posted yet more disappointing results for their investigational cancer medicine MM-121. In the latest study …
NICE gives Lucentis more scope
November 27, 2013Sales and Marketing Lucentis, NICE, Novartis, cnv
An undisclosed price cut from Novartis has been enough to swing NICE towards using the manufacturer’s Lucentis in a fourth …
Bayer targets Norway’s Algeta
November 27, 2013Sales and Marketing Algeta, Bayer, oncology, xofigo
Bayer HealthCare is in the market to buy Norwegian oncology specialist Algeta. The German pharma group has made a bid …
Aesica appoints new site manufacturing manager
November 27, 2013Manufacturing and Production, Research and Development, Sales and Marketing Aesica, catherine dick
Contract development and manufacturing organisation Aesica has appointed Catherine Dick to the role of site manufacturing manager. She will take …
Gilead runs into India patent trouble
November 26, 2013Sales and Marketing Gilead, MSF, hepc, sofosbuvir, sovaldi
Gilead Sciences has run into heavy traffic in India as campaigners attempt to block the company’s patent there on new …
Google diagnostic firm receives scathing FDA warning
November 26, 2013Medical Communications, Research and Development, Sales and Marketing FDA, dna. 23andme, google
The Google-backed DNA testing firm 23andMe has received a warning letter from the FDA saying it cannot continue to market …
Hikma taps Unilife for pre-filled syringes
November 26, 2013Manufacturing and Production Hikma, pre-filled, unilife
Jordanian drugmaker Hikma has signed a strategic-level deal with Unilife for the manufacture of generic injectable drugs using its pre-filled …
FDA U-turn on Avandia
November 26, 2013Sales and Marketing Avandia, CDER, FDA, GSK, diabetes, nissen, type 2
The FDA has delivered a shock verdict that the stringent restrictions on GlaxoSmithKline’s diabetes medicine Avandia should be lifted, despite …
3-V Biosciences hires chief medical officer
November 26, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 3V, biosciences, mcculloch
Clinical-stage biopharma firm 3-V Biosciences has taken on Dr William McCulloch as its chief medical officer. McCulloch brings nearly three …
PPRS deal ‘dreadful’, says EMIG
November 26, 2013Sales and Marketing EMIG, NHS, NICE, PPRS, VBP
The Ethical Medicines Industry Group (EMIG) has slammed the new PPRS plan, calling it a ‘dreadful deal’ for its members. …
GSK expands Montrose API plant with £25m investment
November 25, 2013Manufacturing and Production GSK, Scotland, montrose
GlaxoSmithKline is planning to invest £25 million ($40m) at a facility in Scotland that will take on production of ingredients …
US regulator shows Nexavar green light
November 25, 2013Sales and Marketing Bayer, Cancer, FDA, Nexavar, Onyx, thyroid
The FDA has extended the indication of liver and kidney cancer pill Nexavar to treat late-stage differentiated thyroid cancer. It …
Cancer Research UK invests £100m in research centres
November 25, 2013Research and Development, Sales and Marketing Cancer, Cancer Research UK, UK
Cancer Research UK says it will invest over £100 million across 15 cutting-edge research centres to help get new treatments …
FDA approves Olysio
November 25, 2013Sales and Marketing FDA, Janseen, Janssen, hep C, hepc, olysio, simeprevir
US regulators have approved Janssen Pharmaceuticals’ Olysio, a new therapy to treat chronic hepatitis C virus infection, after a priority …
Patient involvement ‘increases public confidence’ in research
November 25, 2013Research and Development, Sales and Marketing hra, mori, public, rec, research
A new study has shown that public confidence in health research studies can be increased by knowing that patients have …
Hold your horses: M&A is about talent, not just pipelines
November 25, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, mergers, molloy, roik, rsa, talent
The morning mist is rising on the battlefield. At stake: the crown riches and glory of tomorrow’s pharma leadership. The …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
